**Core tip:** There are few studies on the epidemiology and natural history of Wilson's disease in Asia. The present territory-based study was the first to describe both the epidemiology and natural history of Wilson's disease over a long period of time (a span of 17 years from 2000 to 2016) in the Chinese. There was a significant increase in the number of cases of Wilson's disease in Hong Kong. The prognosis was favorable except for those with cirrhosis or concomitant viral hepatitis.

INTRODUCTION
============

Wilson's disease is an autosomal recessive disease with impairment of hepatic excretion of copper, leading to excessive copper accumulation in various organs and tissues\[[@B1]\]. There is a wide spectrum of clinical manifestations including hepatic, neurological, psychiatric and ophthalmological involvements. Nevertheless, some patients may be asymptomatic, and mutational analysis may be needed for a definitive diagnosis\[[@B2]\]. Untreated patients with hepatic involvement carry significant morbidities including cirrhosis and hepatocellular carcinoma (HCC)\[[@B3]-[@B5]\]. Therapies which either chelate the copper (D-penicillamine and trientine) or inhibit its absorption (zinc) are proven to be effective in controlling the disease\[[@B6]\].

There are a few population-based studies on the epidemiology of Wilson's disease in the western population, but the majority were performed before the 1990s. The incidence rate ranges from 17 to 29 per million person-years\[[@B7]-[@B10]\], while the prevalence is reported to be 15-30 cases per million population\[[@B1],[@B11],[@B12]\]. Recently, a genetic study of Wilson's disease concluded that prevalence of Wilson's disease may actually be even higher (1 in 72016)\[[@B13]\]. Studies are even more scarce in Asia, except for one population-based study in Taiwan reporting a low incidence (average annual incidence rate of 2.7 per million person-years) and prevalence (ranging from 8.4 to 16.0 per million) of Wilson's disease between 2000 and 2005\[[@B14]\]. However, the study observation period was short, and prognostic risk factors were not determined.

The long-term outcomes of patients with Wilson's disease are reported in the western population but not in the Asians\[[@B3],[@B4]\]. However, these are retrospective studies and not population-based. In addition, the effect of concomitant chronic viral hepatitis B or C infection on the outcomes of patients with Wilson's disease has not been examined. This is an important factor since around 248 million and 150 million people worldwide have chronic hepatitis B (CHB) and C (CHC) infection, respectively\[[@B15],[@B16]\] While metabolic risk factors (diabetes mellitus, obesity, hypertension as well as metabolic syndrome) predispose CHB and CHC patients to an increased risk of fibrosis/cirrhosis as well as HCC\[[@B17],[@B18]\], whether it will lead to a poorer prognosis in patients with Wilson's disease remains unknown.

Therefore, there is an unmet need for an update of the epidemiology of Wilson's disease as well as more comprehensive identification of risk factors for adverse outcomes in the Asians. This will shed light on the better management of affected patients.

The aims of the present study were to determine the epidemiology and the natural history of Wilson's disease in the Chinese population in Hong Kong. In addition, risk factors for liver transplantation requirement and mortality were determined.

MATERIALS AND METHODS
=====================

Source of data
--------------

We retrieved data from the Clinical Data Analysis and Reporting System (CDARS), an electronic database managed by the Hong Kong Hospital Authority, which is the sole provider of public healthcare services in Hong Kong with about 90% of the healthcare services being covered\[[@B19],[@B20]\]. Important clinical information are all available in the CDRS, which includes patient demographics, death, diagnoses, admissions, clinic visits, procedures, laboratory results, medication prescription and dispensing history\[[@B21]\]. There has been an increasing number of territory-based studies performed using this electronic database\[[@B22]-[@B27]\], with high accuracies of the coding system demonstrated\[[@B24],[@B28]\].

All patients were anonymized in the CDARS, with a unique reference key assigned to each individual. Ethics approval was issued by the Institutional Review Board, The University of Hong Kong and West Cluster of Hospital Authority, Hong Kong.

Study subjects
--------------

The study period commenced from 2000 and ended in 2016. Cases of Wilson's disease from 1999 to 2016 were recognized from the CDARS by using the International Classification of Diseases (ICD)-9 code of 275.1.

Demographics (age, sex, nationality, diagnosis date and death) were retrieved. In addition, information on all diagnoses (including various adverse events and comorbidities) of patients were available for data retrieval.

The incidence rate as well as prevalence of Wilsons's disease were calculated. Adverse liver events (cirrhosis, hepatic complications, HCC and liver transplantation), non-liver outcomes, and mortality were also studied. Risk factors (including concomitant chronic viral hepatitis and metabolic factors) associated with overall and transplant-free survival were determined.

Cases with cirrhosis were identified by the ICD-9 code of 571.5 and the presence of portal hypertension, splenomegaly or cirrhotic complications. Cirrhotic complications were defined with the existence of at least one of the following: ascites, spontaneous bacterial peritonitis, gastroesophageal varices, hepatic encephalopathy, or hepatorenal syndrome. Chronic viral hepatitis referred to either CHB or CHC infection. Metabolic factors included diabetes mellitus, hypertension, dyslipidemia, obesity and alcoholism. Obesity was diagnosed with a body mass index of 25 kg/m^2^ or more in the Asian population\[[@B29]\]. Dyslipidemias are defined as disorders of lipoprotein metabolism with high levels of triglycerides, low-density or non-high-density lipoprotein cholesterol, or low level of high-density lipoprotein cholesterol. The cutoff value depends on the individual patient's cardiovascular risk profile\[[@B30]\]. Smoking status was not usually entered into the electronic database system. Table [1](#T1){ref-type="table"} illustrates the identification of outcomes and covariates.

###### 

International classification of diseases-9 code for outcome and covariates

  ------------------------------------- -----------------------------------------------------------
  Impaired or abnormal liver function   573.8, 794.8
  Hepatitis                             573.3, 571.40, 571.41
  Chronic liver disease                 571.9, 573.9
  Acute liver failure                   570
  Chronic liver failure                 571.8
  Hepatocellular carcinoma              155.0
  Cirrhosis                             571.5
  Viral hepatitis B carrier             V02.61:0
  Viral hepatitis C carrier             V02.62:0
  Sequalae of chronic liver disease     572.8
  Esophageal varices                    456.0, 456.1
  Gastric varices                       456.8
  Ascites                               789.5
  Spontaneous bacterial peritonitis     567.2
  Portal hypertension                   572.3
  Splenomegaly/Hypersplenism            789.1, 789.2, 789.4
  Hepatic encephalopathy                572.2
  Hepatorenal syndrome                  572.4
  Liver transplantation                 V42.7
  Parkinsonism                          332
  Tremor                                781.0
  Dystonic disorder                     333.6
  Convulsion                            780.32
  Tics                                  307.20
  Dementia                              290
  Bipolar affective disorder            296.7
  Depression                            296.2, 296.3, 311
  Anxiety                               300.0
  Organic affective syndrome            293.83
  Psychosis                             295, 293.83
  Personality disorder                  301
  Suicide                               E950
  Hemolytic anemia                      283.10
  Alcoholism                            291, 571.0, 571.1, 571.2, 571.3, 303, 305.0, 980.8, 980.9
  Obesity                               278.0, 278.1
  Diabetes mellitus                     249, 250
  Hypertension                          401-405
  Dysplipidemia                         272.0-272.4
  ------------------------------------- -----------------------------------------------------------

Validation of data
------------------

Diagnosis coding accuracy of the CDARS data was validated by reviewing the eletronic medical records of patients from our center, Queen Mary Hospital. Queen Mary Hospital is a hospital which provides tertiary healthcare services including liver transplantation in Hong Kong.

Statistical analysis
--------------------

Statistical analyses were done by R version 3.2.3 (R Foundation for Statistical Computing) statistical software. We expressed continuous variables in terms of median with interquartile range (IQR), and used Mann-Whitney *U*-test to assess the difference in continuous variables between two groups. We used χ^2^ test or Fisher's exact test for comparing categorical variables. The incidence rate and prevalence of Wilson's disease between 2000 and 2016 were calculated. Poisson regression model was used to evaluate the temporal trends of count data. Variables associated with adverse events were identified by Cox proportional hazards model. The adverse events were analysed by Kaplan-Meier method with statistical significance determined by log-rank test. A two-tailed *P* value \< 0.05 was regarded as statistically significant.

RESULTS
=======

Patient characteristics
-----------------------

Two hundred and eleven patients with Wilson's disease were identified. Patient demographics are shown in Table [2](#T2){ref-type="table"}. Male sex accounted for 49.3% of the cases (male cases 104; female cases 107). There were 170 newly diagnosed cases (male, 84; female, 86). The median follow-up duration was 8.0 years (IQR 5.0 to 14.0 years), with a total follow-up of 1559.5 person-years. Patients were diagnosed with Wilson's disease at a median age of 27.2 years (IQR 17.1 to 38.6 years). Sixty-five patients (30.8%) were diagnosed before the age of 20. Men were diagnosed with Wilson's disease at a similar age as women \[28.5 years (IQR 19.0 to 38.8 years) and 25.0 years (IQR 15.9 to 38.6 years) for men and women, respectively; *P* = 0.326\]. On presentation, nine patients had end-stage cirrhosis and nine had acute liver failure, requiring liver transplantation (8.5% of the total cases). One hundred and seventy-six patients (83.4%) had liver involvement. Of these, 21.6% developed cirrhosis (*n* = 38). Forty-nine patients (23.2%) had neurological and/or psychiatric involvement. Thirty patients (14.2%) had neurological involvement, with parkinsonism being the commonest manifestation (*n* = 15; 50.0%). Twenty-four patients (11.4%) had psychiatric manifestation, with depression being most prevalent (*n* = 9; 37.5%). Four patients (16.7%) had history of suicide. Twenty-one patients (10.0%) had both hepatic and neurological or psychiatric involvement. Non-immune mediated hemolytic anemia occurred in eight patients (3.8%). Seven patients (3.3%) had concomitant chronic viral hepatitis (CHB, 5; CHC, 2), and 17 (8.1%) had metabolic factors.

###### 

Clinical characteristics of patients with Wilson's disease in Hong Kong \[*n* = 211, *n* (%)\]

  **Variables**                                               **Clinical characteristics**
  ----------------------------------------------------------- ------------------------------
  Age                                                         27.9 (18.2-39.7)
  Male                                                        104 (49.3)
  Drug                                                        193 (91.5)
  D-penicillamine[1](#T2FN1){ref-type="table-fn"}             129 (61.6)
  Trientine[2](#T2FN2){ref-type="table-fn"}                   22 (10.4)
  Zinc                                                        42 (19.9)
  Hepatic disease                                             176 (83.4)
  Cirrhosis                                                   38 (21.6)
  Cirrhotic complications                                     19 (10.8)
  Ascites                                                     10 (5.7)
  Spontaneous bacterial peritonitis                           5 (2.8)
  Esophageal varices                                          10 (5.7)
  Gastric varices                                             5 (2.8)
  Hepatic encephalopathy                                      8 (4.5)
  Hepatocellular carcinoma                                    3 (1.7)
  Neurological disease                                        30 (14.2)
  Parkinsonism                                                15 (50.0)
  Tremor                                                      3 (10.0)
  Dystonia                                                    4 (13.3)
  Tics                                                        1 (3.3)
  Dementia                                                    2 (6.7)
  Seizure                                                     7 (23.3)
  Psychiatric disease                                         24 (11.4)
  Depression                                                  9 (37.5)
  Anxiety                                                     2 (8.3)
  Bipolar disorder                                            4 (16.7)
  Organic affective syndrome                                  3 (12.5)
  Psychosis                                                   4 (16.7)
  Personality disorder                                        3 (12.5)
  Suicide                                                     4 (16.7)
  Concomitant hepatic and neurological/psychiatric diseases   21 (10.0)
  Non-immune hemolytic anemia                                 8 (3.8)
  Viral hepatitis                                             7 (3.3)
  Chronic hepatitis B infection                               5 (71.4)
  Chronic hepatitis C infection                               2 (28.6)
  Metabolic factors                                           17 (8.1)
  Diabetes mellitus                                           3 (17.6)
  Hypertension                                                7 (41.2)
  Dyslipidemia                                                4 (23.5)
  Obesity                                                     4 (23.5)
  Alcoholism                                                  4 (23.5)
  Liver transplantation                                       24 (11.3)
  Death                                                       26 (12.3)

Twenty four patients had concomitant zinc therapy during the initial treatment phase or maintenance phase;

Eight patients had concomitant zinc therapy during the initial treatment phase or maintenance phase. Age was expressed as median (years) with interquartile range. Categorical variables were expressed as *n* (%).

Table [3](#T3){ref-type="table"} shows the different medications used in the patients with neurological and/or psychiatric involvement, including anti-parkinson agents, anticonvulsants, benzodiazepines, propranolol, baclofen, tetrabenazine, antidepressants, antipsychotics and lithium.

###### 

The use of different medications in patients with neurological and/or psychiatric involvement

  **Drugs**
  ----------------------------------------------------------------------------------------------------
  Anticonvulsants (carbamazepine and valproate)
  Antidepressants (citalopram and fluoxetine)
  Anti-parkinson agents (levodopa, bromocriptine, amantadine, ropinorole and benzhexol)
  Antipyschotics (clozapine, olanzapine, quetiapine, perphenazine, paliperidone and trifluoperazine)
  Baclofen
  Benzodiazepines (clonazepam, diazepam and lorazepam)
  Lithium
  Propranolol
  Tetrabenazine

When patients were divided into three age strata (\< 20, 20 - 39.9, ≥ 40 years), HCC and mortality were significantly higher in older age groups, while there were no significant differences for other hepatic, neurological or psychiatric manifestations (Table [4](#T4){ref-type="table"}).

###### 

Clinical characteristics of patients with Wilson's disease according to different age strata \[*n* = 211, *n* (%)\]

                             **Age \< 20 (*n* = 65)**   **Age 20-39.9 (*n* = 94)**   **Age ≥ 40 (*n* = 52)**   ***P* value**
  -------------------------- -------------------------- ---------------------------- ------------------------- ---------------
  Hepatic involvement        58 (89.2)                  74 (78.7)                    44 (84.6)                 0.201
  Cirrhosis                  7 (10.8)                   18 (19.1)                    13 (25.0)                 0.128
  Cirrhotic complications    4 (6.2)                    9 (9.6)                      6 (11.5)                  0.584
  Hepatocellular carcinoma   0                          0                            3 (11.5)                  0.014
  Neurological involvement   9 (13.8)                   16 (17.0)                    5 (9.6)                   0.469
  Psychiatric involvement    6 (9.2)                    12 (12.8)                    6 (11.5)                  0.787
  Liver transplantation      11 (16.9)                  11 (11.7)                    2 (3.8)                   0.066
  Death                      4 (6.2)                    9 (9.6)                      13 (25.0)                 0.005

Significant *P* values were bolded.

Incidence rate and prevalence
-----------------------------

Between 2000 and 2016, the average annual incidence rate of Wilson's disease was 1.44 per million person-years. There was a decrease in the annual incidence rate from 1.65 to 1.23 per million person-years (Poisson *P* = 0.010) (Table [5](#T5){ref-type="table"}). The average annual prevalence was 17.93 per million. The annual prevalence increased from 7.80 to 25.20 per million (Poisson *P* \< 0.001).

###### 

Incidence rate and prevalence of Wilson's disease in Hong Kong

  **Yr**   **Total population (million)**   **New cases**   **Total cases**   **Incidence rate (per million person-years)**   **Prevalence (per million)**   **Prevalence ratio of M/F**                                                                
  -------- -------------------------------- --------------- ----------------- ----------------------------------------------- ------------------------------ ----------------------------- ---- ---- ----- ------ ------ ------ ------- ------- ------- ------
  2000     3.28                             3.39            6.67              4                                               7                              11                            24   28   52    1.22   2.06   1.65   7.32    8.26    7.80    0.89
  2001     3.28                             3.43            6.71              6                                               9                              15                            28   36   64    1.83   2.62   2.24   8.54    10.5    9.54    0.81
  2002     3.28                             3.56            6.74              3                                               8                              11                            31   44   75    0.91   2.25   1.63   9.45    12.36   11.13   0.76
  2003     3.26                             3.47            6.73              11                                              7                              18                            40   51   91    3.37   2.02   2.67   12.27   14.7    13.52   0.83
  2004     3.27                             3.52            6.78              9                                               4                              13                            47   54   101   2.75   1.14   1.92   14.37   15.34   14.90   0.94
  2005     3.26                             3.55            6.81              4                                               5                              9                             51   57   108   1.23   1.41   1.32   15.64   16.06   15.86   0.97
  2006     3.27                             3.59            6.86              2                                               3                              5                             52   60   112   0.61   0.84   0.73   15.90   16.71   16.33   0.95
  2007     3.28                             3.63            6.92              2                                               3                              5                             54   63   117   0.61   0.83   0.72   16.46   17.36   16.91   0.95
  2008     3.29                             3.67            6.96              2                                               2                              4                             54   63   117   0.61   0.54   0.57   16.41   17.17   16.81   0.96
  2009     3.28                             3.69            6.97              6                                               10                             16                            60   72   132   1.83   2.71   2.30   18.29   19.51   18.94   0.94
  2010     3.29                             3.73            7.02              9                                               8                              17                            68   80   148   2.74   2.14   2.42   20.67   21.45   21.08   0.96
  2011     3.30                             3.77            7.07              8                                               3                              11                            75   83   158   2.42   0.80   1.56   22.73   22.02   22.35   1.03
  2012     3.33                             3.83            7.15              3                                               2                              5                             77   85   162   0.90   0.52   0.70   23.12   22.19   22.66   1.04
  2013     3.33                             3.86            7.19              2                                               3                              5                             79   87   166   0.60   0.78   0.70   23.72   22.54   23.09   1.05
  2014     3.35                             3.90            7.24              2                                               8                              10                            82   94   175   0.60   2.05   1.38   24.48   24.10   24.17   1.02
  2015     3.37                             3.94            7.31              6                                               0                              6                             86   93   179   1.78   0.00   0.82   25.52   23.60   24.49   1.08
  2016     3.38                             3.96            7.34              5                                               4                              9                             89   96   185   1.48   1.01   1.23   26.33   24.24   25.20   1.09

M: Male; F: Female; T: Total.

Wilson's disease was more commonly diagnosed in the younger age groups, with the incidence rate peaking in the 15- to 19-year age group (Table [6](#T6){ref-type="table"}). For patients aged less than 25 years, the average annual incidence rate ranged from 2.02 to 3.06 per million person-years. For those aged between 25 and 44 years, the average annual incidence rate ranged from 1.71 to 1.97 per million person-years. Patients were less likely to have disease onset at 45 years or older (age group 45-49: 0.86 per million person-years; age group ≥ 50: 0.29 per million person-years).

###### 

Average age-specific incidence rate of Wilson's disease in Hong Kong between 2000 and 2016

          **Case number**   **Incidence rate (per million person-years)**                      
  ------- ----------------- ----------------------------------------------- ---- ------ ------ ------
  0-4     6                 7                                               13   2.81   3.38   2.61
  5-9     3                 7                                               10   1.35   2.73   2.02
  10-14   4                 9                                               13   1.30   2.94   2.09
  15-19   10                12                                              22   2.70   3.43   3.06
  20-24   10                10                                              20   2.64   2.52   2.58
  25-29   9                 6                                               15   2.33   1.21   1.71
  30-34   11                8                                               19   2.72   1.45   1.97
  35-39   9                 10                                              19   1.92   1.70   1.80
  40-44   10                9                                               19   1.92   1.54   1.74
  45-49   4                 5                                               9    0.81   0.92   0.86
  ≥ 50    7                 4                                               11   0.36   0.21   0.29

M: Male; F: Female; T: Total.

Adverse events
--------------

Among the 176 patients with hepatic involvement, 38 had cirrhosis (21.6%). Nineteen patients (10.8%) had cirrhotic complications, with the two most common being the development of ascites (*n* = 10; 5.7%) and esophageal varices (*n* = 10; 5.7%). Around 20% of the cirrhotic cases were men (21 out of 104), while 15.9% were women (17 out of 107) (*P* = 0.416). The median age for the diagnosis of cirrhosis was 33.4 years \[IQR 23.9 to 42.8 years; 32.4 years (IQR 23.7 to 45.5 years) and 34.1 years (IQR 24.4 to 41.4 years) in men and women, respectively; *P* = 0.772\].

Three cases were newly diagnosed with HCC (1.7% of cases with hepatic involvement), all of which developed in men (age at diagnosis ranged from 45.8 to 56.0 years). The 5-year and 10-year cumulative incidences of HCC were 1.3% (95%CI: 0%-3.1%) and 2.3% (95%CI: 0%-4.8%), respectively. The time from diagnosis of Wilson's disease to HCC development ranged from 1.7 to 8 years. All three patients had underlying cirrhosis, and one of them had concomitant CHB infection. None of them received liver transplantation, and two died at the age of 47.2 and 56.8 years.

Liver transplantations were performed in 24 patients (11.3% of all cases; 13.6% of cases with hepatic involvement) \-- 14 for cirrhosis and 10 for acute liver failure. Twelve out of 104 were men (11.1%) and 12 out of 107 were women (11.2%). Five liver transplantations were newly performed between 2000 and 2016. The 5-year and 10-year cumulative incidences of liver transplantation were 1.5% (95%CI: 0%-3.5%) and 4.2% (95%CI: 0%-8.4%), respectively. Patients underwent liver transplantation at a median age of 24.4 years (IQR 18.4 to 37.4 years). There were eight liver transplantation cases in patients aged less than 20 years, 11 cases in those aged between 20 and 39 years, and five cases in those aged between 40 and 59 years.

Twenty-six patients died between 2000 and 2016 \[male cases 16 (15.0%), female cases 10 (9.6%); *P* = 0.182\]. The median time from diagnosis to death for these 26 patients was 4.2 years (IQR 2.1 to 5.0 years). For those newly diagnosed patients receiving long-term treatment (*n* = 154), the 5-year and 10-year rates of overall survival were 92.6% (95%CI: 88.3%-97.1%) and 89.5% (95%CI: 84.1%-95.2%), respectively (Figure [1A](#F1){ref-type="fig"}). By univariate analysis, older age at diagnosis, cirrhosis, HCC , concomitant chronic viral hepatitis and metabolic factors were significant risk factors. By multivariate analysis, cirrhosis (HR 21.75; 95% CI 5.62 to 84.18) was the only independent risk factor, while concomitant chronic viral hepatitis was of borderline significance (HR 7.04; 95% CI 0.94 to 52.81)(Table [7](#T7){ref-type="table"}).

![Kaplan-Meier survival plot. A: Overall survival; B: Transplant-free survival.](WJG-23-7716-g001){#F1}

###### 

HRs and 95%CIs for the association between different covariates and overall survival, transplant-free survival

                                                            **Univariate analysis**   **Multivariate analysis**           
  --------------------------------------------------------- ------------------------- --------------------------- ------- -------------
  Overall survival                                                                                                        
  Age[1](#T7FN1){ref-type="table-fn"}                       1.04                      1.02-1.07                   1.03    0.99-1.08
  Male sex                                                  1.49                      0.52-4.29                           
  Hepatic disease                                           0.92                      0.21-4.13                           
  Cirrhosis                                                 15.42                     5.15-46.18                  21.75   5.62-84.18
  Hepatocellular carcinoma                                  12.42                     2.71-56.93                  2.23    0.38-13.32
  Chronic viral hepatitis[2](#T7FN2){ref-type="table-fn"}   4.95                      1.09-22.44                  7.04    0.94-52.81
  Neurological or psychiatric disease                       1.11                      0.35-3.55                           
  Metabolic factors[3](#T7FN3){ref-type="table-fn"}         4.37                      1.37-13.96                  2.68    0.59-12.17
  Drug                                                                                                                    
  Penicillamine                                             Reference                 \-                                  
  Trientine                                                 2.30                      0.61-8.63                           
  Zinc                                                      0.30                      0.04-2.39                           
  transplant-free survival                                                                                                
  Age[1](#T7FN1){ref-type="table-fn"}                       1.04                      1.01-1.07                   1.03    0.98-1.07
  Male sex                                                  1.45                      0.54-3.88                           
  Hepatic disease                                           1.09                      0.25-4.80                           
  Cirrhosis                                                 21.34                     7.34-61.99                  32.16   8.58-120.52
  Hepatocellular carcinoma                                  11.25                     2.48-50.92                  1.93    0.34-11.07
  Chronic viral hepatitis[2](#T7FN2){ref-type="table-fn"}   4.48                      0.998-20.09                 9.97    1.36-73.05
  Neurological or psychiatric disease                       1.27                      0.44-3.66                           
  Metabolic factors[3](#T7FN3){ref-type="table-fn"}         3.59                      1.16-11.16                  2.51    0.60-10.54
  Drug                                                                                                                    
  D-penicillamine                                           Reference                 \-                                  
  Trientine                                                 1.97                      0.54-7.17                           
  Zinc                                                      0.26                      0.03-1.97                           

Age was treated as a continuous variable in the analysis;

Chronic viral hepatitis was defined as the presence of either chronic hepatitis B or C infection;

Metabolic factors were defined as the presence of one of the following: diabetes mellitus, hypertension, dyslipidemia, obesity or alcoholism. Significant risk factors were bolded.

Figure [2A](#F2){ref-type="fig"} illustrates the comparison of overall survival of patients according to their baseline cirrhosis. Patients without cirrhosis had a significantly higher rate of overall survival (log-rank *P* \< 0.001), with the 5-year and 10-year rates of overall survival being 96.5% (95%CI: 93.2%-99.9%) and 95.3% (95%CI: 91.4%-99.5%), respectively. For patients with cirrhosis, the 5-year and 10-year rates of overall survival were 66.9% (95%CI: 48.3%-92.7%) and 51.0% (95%CI: 30.9%-84.1%), respectively. Figure [2B](#F2){ref-type="fig"} illustrates the comparison of overall survival of patients according to the presence of chronic viral hepatitis. Patients without chronic viral hepatitis had a significantly higher rate of overall survival (log-rank *P* = 0.021), with the 5-year and 10-year rates of overall survival being 93.1% (95%CI: 88.9%-97.6%) and 90.9% (95%CI: 85.8%-96.3%), respectively. For patients with chronic viral hepatitis, the 5-year and 10-year rates of overall survival were 80.0% (95%CI: 51.6%-100%) and 60.0% (95%CI: 29.3%-100%), respectively.

![Kaplan-Meier survival plot for overall survival stratified according to baseline cirrhosis status(A) and presence of chronic viral hepatitis (B).](WJG-23-7716-g002){#F2}

The 5-year and 10-year rates of transplant-free survival were 91.8% (95%CI: 87.3%-96.6%) and 87.4% (95%CI: 81.5%-93.8%), respectively (Figure [1B](#F1){ref-type="fig"}). By univariate analysis, older age at diagnosis, cirrhosis, HCC, concomitant chronic viral hepatitis and metabolic factors were significant risk factors. By multivariate analysis, cirrhosis (HR = 32.16; 95%CI: 8.58-120.52) and concomitant chronic viral hepatitis (HR = 9.97; 95%CI: 1.36-73.05) were independent risk factors (Table [7](#T7){ref-type="table"}).

Figure [3A](#F3){ref-type="fig"} illustrates the transplant-free survival of patients with and without baseline cirrhosis. Patients without cirrhosis had a significantly higher rate of transplant-free survival (log-rank *P* \< 0.001), with the 5-year and 10-year rates of transplant-free survival being 96.5% (95%CI: 93.2%-99.9%) and 95.3% (95%CI: 91.4%-99.5%), respectively. For patients with cirrhosis, the 5-year and 10-year rates of transplant-free survival were 61.2% (95%CI: 42.3%-88.7%) and 33.5% (95%CI: 14.9%-75.2%), respectively. Figure [3B](#F3){ref-type="fig"} illustrates the transplant-free survival of patients with and without chronic viral hepatitis. Patients without chronic viral hepatitis had a significantly higher rate of transplant-free survival (log-rank *P* = 0.032), with the 5-year and 10-year rates of transplant-free survival being 92.3% (95%CI: 87.9%-97.0%) and 88.8% (95%CI: 83.1%-94.9%), respectively. For patients with chronic viral hepatitis, the 5- and 10-year rates of transplant-free survival were 80.0% (95%CI: 51.6%-100%) and 60.0% (95%CI: 29.3%-100%), respectively.

![Kaplan-Meier survival plot for transplant-free survival stratified according to baseline cirrhosis status (A) and presence of chronic viral hepatitis (B).](WJG-23-7716-g003){#F3}

Data validation
---------------

Of the 211 patients with Wilson's disease identified, 80 patients (37.9%) had follow-up in our hospital. After cross validating with the medical records, 77 were confirmed to have Wilson's disease (positive predictive value (PPV) of 96.3%).

Of the 77 patients, we could not ascertain in 10 patients whether they were index cases or diagnosed by family screening. For the remaining 67 cases, 59 (88.1%) were index cases and 8 (11.9%) were diagnosed by family screening. All cases were diagnosed of Wilson's disease in accordance to the AALSD or EASL guidelines. Sixty-five patients (84.4%) had liver manifestations, while 25 (32.5%) had neurological and/or psychiatric manifestations \[18 (23.4%) and 11 (14.3%) had neurological and psychiatric manifestations, respectively\].

DISCUSSION
==========

Currently, population-based studies on the epidemiology as well as the natural history of Wilson's disease are lacking in both the western and Asian populations, and the majority of them were done before the 1990s. The present territory-based study was the first to describe both the epidemiology and natural history of Wilson's disease over a long period of time (a span of 17 years from 2000 to 2016) in the Chinese. The population-based nature of this study, in which the data were retrieved via electronic search of hospital medical registry, enables complete capture of all cases under the care of our public health system. This helps to minimize selection bias inherent in studies conducted in tertiary referral centers or selected hospitals. Cases were identified by ICD-9 coding, with local studies showing high coding accuracies\[[@B24],[@B28]\]. We also confirmed a PPV of 96.3% for the coding accuracy of Wilson's disease in the CDARS.

The incidence rate and prevalence of Wilson's disease were estimated to be 17 to 29 per million person-years\[[@B8],[@B9]\] and 30 per million, respectively\[[@B1],[@B11]\] In comparison, the estimates from our study were lower, with an average annual incidence rate of 1.44 per million person-years, and an average annual prevalence of 17.93 per million. These estimates were in line with what were reported in Taiwan between 2000 and 2005 (an average annual incidence rate of 2.7 per million person-years and a prevalence ranging from 8.4 to 16.0 per million). The lower incidence rate may be partly due to under diagnosis. However, whether Wilson's disease is genuinely less common in Asia requires confirmation from more population-based studies.

From the present study, the annual incidence rate of Wilson's disease in Hong Kong had been decreasing, from 1.65 to 1.23 per million person-years between 2000 and 2016. This is likely attributed to the ageing population. As shown in Table [4](#T4){ref-type="table"}, the incidence rate of Wilson's disease peaked in the 15- to 19-year age group (3.06 per million person-years), while it was extremely low among individuals aged 45 or more. Between 2000 and 2016, population aged less than 20 has decreased from 1.59 million to 1.17 million, while the population aged 50 or more has increased from 1.63 million to 2.92 million in Hong Kong\[[@B31]\]. On the other hand, the prevalence of Wilson's disease has been increasing, from 7.80 to 24.49 per million. This is likely related to the availability of effective treatment. It has been shown that treatment is associated with hepatic and neurological improvements in 82%-90% and 55%-69% of patients, respectively\[[@B4],[@B6]\].

In the current study, the median age at diagnosis was 27.2 years, with the highest incidence rate observed in the 15- to 19-year age group. The proportions of cases in different age strata in our study \[age \< 20: 58 cases (30.8%); age 20-39: 73 cases (44.5%); age ≥ 40: 39 cases (24.6%)\] were consistent with that reported by the Taiwanese population-based study \[age \< 20: 115 cases (37.5%); age 20-39: 127 cases (41.4%); age ≥ 40: 65 cases (21.2%)\]\[[@B14]\]. Men and women were equally affected as shown in our study and also previous studies\[[@B3],[@B4],[@B14],[@B32]\]. The proportion of patients with neurological and/or psychiatric involvement was relatively low in our study (*n* = 49, 23.2%), although some studies also reported a similar rate of 24%-27%\[[@B3],[@B33]\]. As for our center, 25 out of 77 patients (32.5%) had neurological and/or psychiatric involvement. This slightly higher proportion of neurological/psychiatric involvement is likely to be explained by the fact that our center is a tertiary referral hospital and is the only center which provides liver transplantation services in our locality.

However, a significant proportion of patients with hepatic involvement still had liver-related complications, with 21.6% having cirrhosis, 10.8% having cirrhotic complications, 1.7% developing HCC, and 13.6% undergoing liver transplantations. Around 12% of the total cases died during the observation period, with the 5-year and 10-year rates of overall survival being 92.6% and 89.5%, respectively.

Factors that could modify the transplant-free survival included the presence of cirrhosis (HR = 32.16) and concomitant chronic viral hepatitis (HR = 9.97). This highlights the importance of early diagnosis and treatment in reducing the copper load in the body to prevent development of cirrhosis. Future prospective studies with larger sample size are required to ascertain whether early treatment to suppress hepatitis B virus replication and to cure hepatitis C virus infection will be useful in improving the prognosis of patients with concomitant chronic viral hepatitis. The presence of metabolic factors was shown to be associated with lower transplant-free survival by univariate but not multivariate analysis. There are two possible reasons. First, as metabolic factors are associated with increasing age and cirrhosis\[[@B17],[@B18],[@B34]\], the potential risk of metabolic factors per se as shown by univariate analysis was attenuated after adjusting for the effect of age and cirrhosis in multivariate analysis. Second, the present study may be underpowered to detect this potential effect due to the relatively small sample size.

There are some limitations of the current study. First, a small proportion of healthcare services (around 10%) is not covered by the Hospital Authority\[[@B19]\], and hence some patients attending private hospitals will not be captured in the CDARS. As such, the incidence rate and prevalence of Wilson's disease might be underestimated. Nevertheless, the majority of these patients are likely to be captured in the CDARS eventually, because of preference for long-term follow-up in the public hospitals or having consultation for other illnesses in our locality. Second, information regarding biochemical response to various treatment (D-penicillamine, trientine and zinc) could not be retrieved. Third, whether Wilson's disease was diagnosed in accordance to the international guidelines (AALSD or EASL guidelines) could not be confirmed in other centers. However, this limitation was unlikely to have significant impact as it is the standard practice that all patients with suspected Wilson's disease in Hong Kong are referred to hepatologists. As an example, all 77 cases who followed up in our center were diagnosed according to the international guidelines. Fourth, we could not ascertain whether these patients were index cases or were detected by family screening. As for our center, only 8 cases (11.9%) were diagnosed by family screening. In addition, diagnosis of Wilson's disease in patients with neurological symptoms is usually delayed for a longer time from onset than in patients with hepatic symptoms\[[@B35]\]. The incidence rate of Wilson's disease in our cohort should therefore be interpreted in this context. Lastly, some of the medications used to treat the neurological and/or psychiatric symptoms (*e.g*., anticonvulsants) could potentially lead to deranged liver function, which may be wrongly regarded as liver involvement due to Wilson's disease by simply referring to the ICD coding.

These limitations may be addressed by collaboration between all public and private hospitals in the future. In this way, an even more precise estimate of the epidemiology of Wilson's disease could be derived, and other potential risk factors for reduced transplant-free survival (*e.g*., metabolic factors) could be further investigated.

In conclusion, the epidemiology of Wilson's disease was described in a well defined Chinese population, with identification of risk factors for overall and transplant-free survival. There was a significant increase in the prevalence of Wilson's disease in Hong Kong. Early diagnosis and treatment as well as control of concomitant chronic viral hepatitis to improve prognosis could potentially reduce the disease complications.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

There are few studies on the epidemiology and natural history of Wilson's disease in the Chinese population. The authors conducted a territory-based study in Hong Kong (HK) with a population of 7.3 million to address this issue.

Research motivation
-------------------

Epidemiology data are important for recognizing the temporal trend of a particular disease, understanding the natural history and risk factors, as well as for resource allocation.

Research objectives
-------------------

To investigate the epidemiology and natural history of Wilson's disease in the Chinese population.

Research methods
----------------

Data were retrieved from the Clinical Data Analysis and Reporting System (CDARS) and Clinical Management System (CMS) of the Hong Kong Hospital Authority. The study observation period was from 2000 to 2016. Cases of Wilson's disease between 1999 and 2016 were identified from CDARS by the International Classification of Diseases (ICD)-9 code of 275.1. The incidence rate and prevalence of Wilson's disease between 2000 and 2016 were calculated. Evaluation of the count data and temporal trends was assessed by Poisson regression model. Cox proportional hazards model was used to identify variables that were associated with adverse outcomes. Kaplan-Meier method was used to analyze the adverse outcomes.

Research results
----------------

The authors identified 211 patients (male-to-female ratio 0.97:1; median age 27.2 years, IQR: 17.1-38.6 years; median follow-up 8.0 years, IQR: 5.0-14.0 years). The average annual incidence rate and prevalence were 1.44 per million person-years and 17.93 per million, respectively. Between 2000 and 2016, the annual incidence rate decreased from 1.65 to 1.23 per million person-years (Poisson *P* = 0.010), while the annual prevalence increased from 7.80 to 25.20 per million (Poisson *P* \< 0.001). Among the 176 patients with hepatic involvement, 38 (21.6%) had cirrhosis, three (1.7%) developed hepatocellular carcinoma, 24 (13.6%) underwent liver transplantations, and 26 (14.8%) died. Seven patients had concomitant chronic viral hepatitis B or C. The 5- and 10-year overall survival rates were 92.6% and 89.5%, and for transplant-free survival rates 91.8% and 87.4%, respectively. Cirrhosis and possibly chronic viral hepatitis were associated with poorer overall survival.

Research conclusions
--------------------

There was a considerable increase in the prevalence of Wilson's disease in the Chinese population. The long-term survival was good except in patients with cirrhosis or concomitant viral hepatitis.

Research perspectives
---------------------

The epidemiology of Wilson's disease was described in a well defined Chinese population, and factors associated with overall survival and transplant-free survival were identified. Future collaboration with the hepatology units from all public and private hospitals is warranted to allow for an even more precise estimate of the epidemiology of Wilson's disease and to investigate other potential risk factors for reduced transplant-free survival (*e.g*., metabolic factors).
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